Theravance Biopharma, Inc.
NASDAQ:TBPHBiotechnology
-$0.07 today
- Market cap
- $882.64M
- Beta
- 0.18
- P/E (TTM)
- 7.4
- EPS (TTM)
- $2.23
Volume 10.02M
Average 0.43M
TBPH Total Current Assets
All assets expected to be converted to cash or used up within one year.
Theravance Biopharma, Inc.NASDAQ: TBPH
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 177.9% from a year ago
Total current assets stood at $417.63M at the end of Q1 FY2026, up 177.9% from a year earlier and down 0.2% from the prior quarter. Over 3 fiscal years it compounded at +5.8% a year.
Context
- Total current assets amounted to 88.4% of total assets at the end of Q1 FY2026, up 44.7 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +177.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 418.46M USD
- Year-over-year change
- +159.8%
- 4-year CAGR
- +13.8%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 418.46M | +159.8% |
| FY2024 | 2024-12-31 | 161.07M | +20.6% |
| FY2023 | 2023-12-31 | 133.54M | -62.2% |
| FY2022 | 2022-12-31 | 353.46M | +41.5% |
| FY2021 | 2021-12-31 | 249.87M | — |
Total Current Assets vs competitors
How TBPH compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +177.9% is the highest of 9, against a peer median of +11.1%.
- Total current assets amounts to 88.4% of total assets for TBPH, versus a peer median of 92.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $677.55M USD | +103.9% | +12.5% | 92.0% | |
| Mar 2026 | $522.99M USD | -43.9% | -41.1% | 51.0% | |
| Mar 2026 | $498.53M USD | +0.6% | +42.4% | 93.3% | |
| Mar 2026 | $417.63M USD | +177.9% | +5.8% | 88.4% | |
| Mar 2026 | $394.61M USD | +21.6% | +1.0% | 95.8% | |
| Mar 2026 | $348.7M USD | +87.7% | +22.2% | 99.8% | |
| Dec 2025 | $280.35M USD | -48.8% | +7.1% | 84.0% | |
| Mar 2026 | $268.37M USD | +35.6% | +84.4% | 98.5% | |
| Mar 2026 | €201.65M EUR | -29.8% | -19.4% | 54.1% | |
| Peer median (excluding TBPH) | — | +11.1% | +9.8% | 92.7% | |
Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 89.96M | 298.17M | 39.55M | 37.8M | 167.81M |
| Short-term Investments | 83.51M | 29.31M | 62.88M | 50.55M | 147.55M |
| Net Receivables | 57.6M | 16.79M | 17.47M | 68.44M | 95.54M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 8.56M | 7.68M | 11.6M | 4.2M | 7.56M |
| Total Current Assets | 249.87M | 353.46M | 133.54M | 161.07M | 418.46M |
| Property, Plant & Equipment (Net) | 53.35M | 52M | 45.36M | 35.77M | 30.27M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 68.37M | 0 | 0 | 0 | 14.35M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.23M | 201.94M | 203.1M | 157.32M | 22.5M |
| Total Non-current Assets | 124.95M | 253.94M | 248.46M | 193.09M | 67.11M |
| Total Assets | 374.82M | 607.4M | 382M | 354.16M | 485.57M |
| Account Payables | 3.1M | 1.55M | 1.52M | 2.24M | 2.57M |
| Short-term Debt | 17.44M | 0 | 0 | 0 | 10.95M |
| Tax Payables | 0 | 0 | 0 | 5.85M | 0 |
| Deferred Revenue | 98K | 24K | 0 | 0 | 0 |
| Other Current Liabilities | 25.15M | (24K) | 12.88M | 0 | 6.91M |
| Total Current Liabilities | 58.59M | 28.72M | 24.77M | 32.09M | 38.3M |
| Long-term Debt | 599.39M | 0 | 0 | 0 | 32.8M |
| Deferred Tax Liabilities | 240K | 0 | 0 | 0 | 85.68M |
| Deferred Revenue (Non-current) | 310K | 192K | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.18M | 91.29M | 99M | 107.42M | 313K |
| Total Non-current Liabilities | 654.81M | 136.89M | 144.24M | 146.53M | 150.55M |
| Total Liabilities | 713.39M | 165.6M | 169M | 178.62M | 188.85M |
| Common Stock | 1K | 1K | 0 | 0 | 1K |
| Retained Earnings | (1.73B) | (853.91M) | (909.1M) | (965.52M) | (859.63M) |
| Accumulated OCI | (0) | (15K) | (65K) | 7K | 61K |
| Other Stockholders Equity | 0 | 0 | (0) | (0) | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (338.57M) | 441.8M | 213M | 175.55M | 296.72M |
| Total Debt | 669.52M | 52.16M | 49.16M | 49.82M | 75.5M |
| Net Debt | 579.56M | (246.01M) | 9.61M | 12.02M | (92.31M) |
Theravance Biopharma, Inc.
NASDAQ:TBPH
Intrinsic Alpha fair value
Locked
Current Price
$17.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.